GAR's Sustainability Report 2024 Shows Company, Customers and Communities Growing Together with Purpose
SINGAPORE, May 30, 2025 /PRNewswire/ -- Golden Agri-Resources (GAR) today published its Sustainability Report 2024, covering a year that saw the company establish the scale and scope of its climate ambitions while continuing to deliver on core commitments to tackle deforestation, enhance traceability and promote thriving, resilient agricultural communities.
GAR Chairman and Chief Executive Officer, Mr. Franky O. Widjaja, explained how the company's sustainability foundations have helped GAR to navigate a year of global challenges, from economic shifts and evolving regulatory demands to extreme weather conditions.
"The world is changing, and so is the future of agribusiness," he said. "At GAR, sustainability isn't just a part of our business strategy; it is our business strategy. We believe that sustainability leadership starts with action; with choices that reflect our values and shape a better future."
For the first time, GAR has published a double materiality assessment, addressing both the company's impact on environmental and social issues and how these topics may influence GAR's operations, long-term resilience, and financial performance. In addition to preparing the company for upcoming reporting requirements, this assessment validates GAR's priorities for action on sustainability.
Widjaja continued: "As extreme weather and regulations intensify, investing in responsible agriculture matters more than ever. Our 2024 theme of Growing Together with Purpose reflects a year of evolution for GAR's sustainability policies and practice. Over the past year, we have set bold targets for emissions reduction by 2030 and developed a new sustainability framework, Collective for Impact, that provides a clear path forward for the next stage of our sustainability journey – a journey we're taking together with partners, suppliers and smallholders."
Notable developments include:
Launching Collective for Impact
Since 2015, the GAR Social and Environmental Policy (GSEP) has been the foundation of the company's sustainability commitments, implemented in its own operations and across the company's palm oil supply chain in Indonesia.
Now, GAR has launched a new framework, Collective for Impact, marking the next phase of its sustainability ambitions. Covering three key areas: Sourcing Responsibly, Caring for our Planet, and Empowering People, this new business strategy extends beyond GAR's Indonesian palm oil supply chain to include its entire business and value chain, operationally and geographically.
Anita Neville, GAR's Chief Sustainability and Communications Officer, described how this framework builds on the company's existing initiatives to address critical areas for action. "It has never been more urgent to act on climate change, eliminate exploitation, and protect natural ecosystems," she said.
"We know that what got us here will not necessarily get us where we want and need to go," she continued. "Collective for Impact strengthens our resilience, creates long-term value and builds trust to keep us ahead of global expectations. This is not just a sustainability vision; it is a business strategy that touches every part of GAR."
Advancing Net Zero Commitments
In 2024, GAR set bold 2030 targets to cut absolute emissions as a milestone on its pathway to net zero emissions by 2050. The company will cut Forest, Land, and Agriculture (FLAG) emissions by 30% and non-FLAG emissions by 42% from its 2022 baseline.
Last year, GAR reduced Scope 1 and 2 emissions from its direct operations by 3% through continued implementation of No Deforestation, No Peat and No Exploitation (NDPE) policies, coupled with energy efficiency initiatives and increased renewable energy use.
However, GAR's total emissions increased by 7% year on year, from 32.7 million tonnes of CO2 equivalent in 2023 to 35 million tonnes in 2024, driven by a 10% increase in Scope 3 emissions. These supply chain emissions account for 79% of GAR's total carbon footprint, underscoring the critical role of ongoing supplier engagement and collecting first party emissions data; two core pillars of the company's Scope 3 reduction efforts.
Leading in Transparency and Traceability
GAR has continued to map its Indonesian palm oil supply chain and has now reached 99.5% Traceability to the Plantation (TTP). The company is intensifying efforts to address the final 0.5% of TTP, addressing variability within its supply chain and extending its partnerships with smallholders to implement traceability while supporting them to improve yields and livelihoods.
Elsewhere, the company has successfully expanded its traceability commitments to its other commodities, implementing 100% Traceability to the Mill (TTM) for soy, sugar, sunflower and coconut globally.
The company has also launched the blockchain-powered SmartTrace system, giving users a window on the full journey of a palm oil product from plantation to purchase. Together with satellite monitoring, mapping, and supplier transformation initiatives, GAR is continuing to ensure responsible production across its supply chain, helping customers to prepare for the European Union Deforestation Regulation (EUDR) and future regulations.
Action for Communities
GAR's Bright Future Initiative continues to help communities build better livelihoods. In 2024, the company supported 189 projects, and empowering 113 Micro, Small, and Medium Enterprises (MSMEs) with skills from farming and technology to operations training, helping them grow and reach new markets.
About Golden Agri-Resources Ltd (GAR)
GAR is a leading fully-integrated agribusiness company. In Indonesia, it manages an oil palm plantation area of more than 500,000 hectares (including plasma smallholders) as of 31 March 2025. It has integrated operations focused on the technology-driven production and distribution of an extensive portfolio of palm-based products throughout its established international marketing network.
Founded in 1996, GAR was listed on the Singapore Exchange in 1999 and has a market capitalisation of US$ 2.6 billion as of 31 March 2025. Flambo International Limited, an investment company, is GAR's largest shareholder, with a 50.56% stake. In addition, GAR's subsidiary, PT SMART Tbk was listed on the Indonesia Stock Exchange in 1992.
As an integrated agribusiness, GAR delivers an efficient end-to-end supply chain, from responsible production to global delivery. In Indonesia, its primary activities include cultivating and harvesting oil palm trees; the processing of fresh fruit bunch into crude palm oil (CPO) and palm kernel; refining CPO into value-added products such as cooking oil, margarine, shortening, biodiesel and oleo-chemicals; as well as merchandising palm products globally.
GAR's products are delivered to a diversified customer base in over 110 countries through its global distribution network with shipping and logistics capabilities, destination marketing, onshore refining and ex-tank operations. GAR also has complementary businesses such as soybean-based products in China, sunflower-based products in India, and sugar businesses.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/gars-sustainability-report-2024-shows-company-customers-and-communities-growing-together-with-purpose-302468171.html
SOURCE Golden Agri-Resources
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
USI Partners with Customer on GPS Bike Computer Project, Delivering Durable Rugged Design
SHANGHAI, June 4, 2025 /PRNewswire/ -- Universal Scientific Industrial (Shanghai) Co., Ltd., USI, a global leader in electronic design and manufacturing services, is collaborating with a customer to develop a GPS bike computer through its Joint Design Manufacturing (JDM) service. The project responds to increasing global demand for high-performance, durable cycling electronics in a rapidly expanding market. According to a report by Global Industry Analysts, Inc., the global market for GPS bike computers was valued at $1.2 billion in 2024 and is expected to grow to $1.7 billion by 2030, with a compound annual growth rate (CAGR) of 5.0% from 2024 to 2030. This market is driven by rising interest in outdoor activities, fitness tracking, and smart mobility solutions. However, durability remains a top concern among end-users, particularly cyclists who operate in extreme environmental conditions and expect reliable performance from their gear. With over two decades of experience in designing and manufacturing rugged, thinner, and lighter devices, USI is uniquely positioned to address these challenges. The company works closely with customers to understand their pain points and long-term product strategies. By analyzing the product roadmap and selecting key components, USI's engineering team proposes a rugged design that emphasizes durability, reliability, and resistance to harsh conditions. "Our JDM model allows customers to benefit from USI's turnkey solutions—from concept design and system integration to volume production," said Mark Zou, the Director of the Vertical Mobility Solutions Center, USI. For the GPS bike computer project, we delivered a robust design solution that meets both functional performance and ruggedness requirements, ensuring the device can withstand tough terrains, vibration, and weather elements." USI's continued investment design expertise and customer-centric innovation supports the growing needs of the smart mobility market and reflects its commitment to quality, reliability, and partnership. About USI (SSE: 601231) USI, Universal Scientific Industrial (Shanghai) Co., Ltd., is a global leader in electronic design and manufacturing as well as a leader in the field of SiP (System-in-Package) technology. With Asteelflash and Hirschmann Car Communication, USI has 30 production and service locations across four continents of Asia, Europe, the Americas, and Africa, and offers customer diversified electronic products with D(MS)2 services: Design, Manufacturing, Miniaturization, Industrial software, and hardware Solutions, and material procurement, logistics and maintenance Services. USI is a subsidiary of ASE Technology Holding Co., Ltd. (TWSE: 3711, NYSE: ASX). To learn more, please visit and engage with us on LinkedIn and YouTube. View original content: SOURCE USI Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints
Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinically meaningful improvement compared to placebo in all primary, key secondary, and secondary endpoints Denifanstat demonstrated a favorable safety and tolerability profile Denifanstat was 98% and 178% more effective than U.S. Food and Drug Administration (FDA)-approved sarecycline and doxycycline with regard to placebo-adjusted percent treatment success, respectively, 18.6% for denifanstat versus 9.4% for sarecycline, 18.6% versus 6.7% for doxycycline Denifanstat was 60% more effective than FDA-approved clascoterone cream with regard to placebo-adjusted percent treatment success, 18.6% for denifanstat versus 11.6% for clascoterone cream, respectively The exceptional efficacy of denifanstat coupled with its favorable safety profile in the Phase III trial provides a potential major break-through for the treatment of acne HONG KONG, June 3, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that denifanstat (ASC40), a first-in-class, once-daily oral small molecule fatty acid synthase (FASN) inhibitor, meets all primary, key secondary, and secondary endpoints in the Phase III clinical trial for the treatment of moderate to severe acne vulgaris (NCT06192264). The Phase III clinical trial was a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of denifanstat once-daily oral tablet in 480 patients with moderate to severe acne vulgaris. Patients were enrolled and randomized into one active treatment arm and one placebo control arm at the ratio of 1:1 to receive 50 mg denifanstat oral tablet once daily or matching placebo for 12 weeks. Baseline characteristics were well balanced between denifanstat and placebo arms. Table 1 summarizes some of baseline characteristics. Primary, key secondary, and secondary endpoints can be found in Table 2. Primary endpoints included the percent treatment success (defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease in IGA from baseline at week 12), the percent reduction from baseline in total lesion count, and the percent reduction from baseline in inflammatory lesion count. At week 12, percent treatment success was 33.2% compared to 14.6% for placebo, p<0.0001, percent reduction from baseline in total lesion count was 57.4% compared to 35.4% for placebo, p<0.0001, and percent reduction from baseline in inflammatory lesion count was 63.5% compared to 43.2% for placebo, p<0.0001. The key secondary endpoint, percent reduction from baseline in non-inflammatory lesion count at week 12, was 51.9% compared to 28.9% for placebo, p<0.0001. Denifanstat demonstrated a favorable safety and tolerability profile following 12 weeks of once-daily oral administration at 50 mg. The incidence rates of treatment-emergent adverse events (TEAEs) were comparable between denifanstat and placebo. No incidence rates of TEAEs related to study drug in any category exceeded 10%. Only two categories of TEAEs had an incidence rate of more than 5% (6.3% dry skin in denifanstat-treated patients versus 2.9% in the placebo group; 5.9% dry eye in denifanstat-treated patients versus 3.8% in the placebo group). All denifanstat-related adverse events (AEs) were mild or moderate. There were no denifanstat-related grade 3 or 4 AEs and no denifanstat-related serious AEs (SAEs). No deaths were reported. The mechanisms of action of denifanstat for the treatment of acne are (1) direct inhibition of facial sebum production, through inhibition of de novo lipogenesis (DNL) in human sebocytes; and (2) inhibition of inflammation, through decreasing cytokine secretion and Th17 differentiation. Denifanstat's unique mechanism of action directly reduces one of the main underlying causes of acne which is the overproduction of sebum. This makes denifanstat unique as most other acne treatments do not treat the underlying cause of the condition. "We are extremely pleased with the topline results of our Phase III trial. Denifanstat tablets demonstrated impressive efficacy beyond treatment success, showing significant reductions in total lesion count, inflammatory lesion count, and non-inflammatory lesion count. We are excited to be submitting this innovative treatment with the China National Medical Products Administration (NMPA) soon." said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. Table 3 highlights the excellent efficacy of denifanstat in a non-head-to-head comparison to other commonly used oral and topical acne treatments. Denifanstat demonstrated its exceptional efficacy across multiple key metrics compared to sarecycline, doxycycline and clascoterone cream. With regard to the placebo-adjusted percent treatment success and the placebo-adjusted percent reduction from baseline in inflammatory lesion count, denifanstat was 98% and 30% more effective than sarecycline, respectively, 178% and 178% more effective than doxycycline, respectively, and 60% and 59% more effective than clascoterone cream, respectively. With regard to the placebo-adjusted percent reduction from baseline in total lesion count, denifanstat was 189% and 85% more effective than doxycycline and clascoterone cream, respectively. With regard to the placebo-adjusted percent reduction from baseline in non-inflammatory lesion count, denifanstat was 411% and 102% more effective than sarecycline and clascoterone cream, respectively. Denifanstat has the potential to be a first-in-class, once-daily, oral acne therapeutic, potentially offering both exceptional efficacy and patient compliance with a favorable safety and tolerability profile. Compared to other oral acne treatments, denifanstat provides outstanding efficacy with excellent safety. There is no potential for antibiotic resistance or off target effects which can occur with tetracycline derivatives and no reported denifanstat-related severe AEs such as hepatotoxicity, hearing impairment and depression which are seen with isotretinoin. Denifanstat should also provide better adherence to treatment compared to topical therapies: an estimated 30% to 40% of patients do not adhere to their topical treatments[1]. Denifanstat is licensed from Sagimet Biosciences Inc. (Nasdaq: SGMT) for exclusive rights in Greater China. "The Phase III clinical trial results for denifanstat are highly encouraging. The data demonstrate statistically significant improvements in treatment outcomes for moderate-to-severe acne patients, with percent treatment success of 33.2%, total lesion count reduction of 57.4% from baseline, inflammatory and non-inflammatory lesion counts decreasing by 63.5% and 51.9%, respectively, while maintaining a favorable safety and tolerability profile. Denifanstat's first-in-class mechanism targeting FASN directly addresses a key cause for acne, establishing it as a groundbreaking therapeutic approach in acne treatment." said Prof. Leihong Xiang, Chief Physician of Dermatological Department, Huashan Hospital, Fudan University, Executive Deputy Director of Institute of Dermatology, Fudan University, Deputy Director of Dermatology Division of Chinese Medical Doctor Association and principal investigator of denifanstat Phase III trial for moderate to severe acne. [1] Purvis CG, Balogh EA, Feldman SR. Clascoterone: How the Novel Androgen Receptor Inhibitor Fits Into the Acne Treatment Paradigm. Ann Pharmacother. 2021;55(10):1297-1299. doi:10.1177/1060028021992055. Table 1. Baseline characteristics of Phase III trial of denifanstat Baseline characteristics 50 mg denifanstat, oral, oncedaily (n=240) Placebo, oral, once daily (n=240) Total lesion count 102.2 102.1 Inflammatory lesion count 42.1 43.1 IGA=3 (moderate), % 85.8 85.8 IGA=4 (severe), % 14.2 14.2 Table 2. Efficacy endpoints of 50 mg denifanstat oral, once daily at week 12 versus placebo (intent-to-treat, ITT, analysis) Efficacy endpoints (1) 50 mg denifanstat, oral, once daily (n=240) Placebo, oral,once daily (n=240) Placebo adjusted p value Percent treatment success (2) (primary endpoint) 33.2 14.6 18.6 <0.0001 Percent reduction from baseline in total lesion count (primary endpoint) 57.4 35.4 22.0 <0.0001 Percent reduction from baseline ininflammatory lesion count (primary endpoint) 63.5 43.2 20.3 <0.0001 Percent reduction from baseline in non-inflammatory lesion count (key secondary endpoint) 51.9 28.9 23.0 <0.0001 Absolute reduction from baseline intotal lesion count (secondary endpoint) 58.3 36.2 22.1 <0.0001 Absolute reduction from baseline in inflammatory lesion count (secondaryendpoint) 26.6 18.4 8.2 <0.0001 Notes: (1) All efficacy endpoints are least square means.(2) Treatment success is defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point decrease in IGA from baseline at week 12. Table 3. Denifanstat compared to other commonly used acne treatments (not head-to-head comparison) Category Denifanstat (n=240) Sarecycline(1) (n=1002) Doxycycline(2) (n=216) Clascoterone cream(3) (n=722) Baseline characteristics Total lesion count 102.2 72.4 71.7 103.6 Inflammatory lesion count 42.1 30.0 33.6 42.7 IGA=3 (moderate), % 85.8 85.2 93.5 82.7 IGA=4 (severe), % 14.2 14.9 6.5 17.3 Efficacy endpoints at week 12 Placebo-adjusted percenttreatment success 18.6 9.4 6.7 11.6 Placebo-adjusted percent reductionfrom baseline in total lesion count 22.0 NA 7.6 11.9 Placebo-adjusted percent reductionfrom baseline in inflammatorylesion count 20.3 15.6 7.3 12.8 Placebo-adjusted percent reduction from baseline in non-inflammatorylesion count 23.0 4.5 NA 11.4 Notes: (1) The sarecycline data represent an analysis of its two Phase III clinical trials, with values expressed as means. The data are from Moore, A., et al., J Drugs Dermatol 2018 Vol. 17 Issue 9 Pages 987-996. The non- inflammatory lesion count data are from FDA ( The doxycycline data at week 16 are from Moore, A., et al., J Drugs Dermatol 2015 Vol. 14 Issue 6 Pages 581-6.(3) The clascoterone cream (1%) data represent an analysis of its two Phase III clinical trials, with values expressed as means. The data are from Hebert. A, et al., JAMA Dermatology 2020 Vol. 156 Issue 6, DOI: 10.1001/jamadermatol.2020.0465. About Ascletis Pharma Inc. Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange ( covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on metabolic diseases by addressing unmet medical needs from a global perspective. Ascletis has multiple clinical stage drug candidates in its metabolic disease pipeline. For more information, please visit Contact: Peter VozzoICR Healthcare443-231-0505 (U.S.) Ascletis Pharma Inc. PR and IR teams+86-181-0650-9129 (China)pr@ ir@ View original content: SOURCE Ascletis Pharma Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Appian Connected Claims 2.0 Transforms Insurance Claims Management with AI
Appian is named a 'Leader' in Everest Group's 'AI-enabled Claims Management Systems for Property & Casualty (P&C) Insurance – Products PEAK Matrix®' for 2025 LONDON, June 4, 2025 /PRNewswire/ -- Appian (NASDAQ: APPN) today announced the launch of Connected Claims 2.0, an AI-powered solution designed to provide a unified claims workflow. Everest Group also named Appian a Leader in AI-enabled Claims Management Systems for Property & Casualty (P&C) Insurance – Products PEAK Matrix® Assessment 2025. Connected Claims 2.0 leverages Appian's Case Management Studio, AI agents, and data fabric to offer streamlined, data-driven, and AI-powered automated processes. Driven by rapid digital transformation, the global insurance claims services processing market is projected to reach $638.3 billion by 2032. Connected Claims 2.0 will support insurers through this growth with a unified claims workflow that accelerates processing, enhances fraud detection, combats inconsistent handling, data management issues and improves customer satisfaction. Connected Claims 2.0 offers a fully integrated, AI-powered platform with customisable workflows and a superior user experience, featuring a single pane of glass, AI-powered data insights, real-time data access, and automated regulatory compliance management. Appian's Connected Claims solution brings powerful AI-driven support to every adjuster, making it easier to manage the demands of a document-heavy claims environment. With capabilities like data classification, document summarisation, contextual chat, and next-best-action recommendations, AI accelerates work and improves decision-making. The next generation of the solution introduces the Appian AI Document Centre, enabling users to easily train models to extract data from unstructured documents. This means faster intake, more accurate data capture, and seamless handoff for tasks like fraud detection and automated triage. Over time, users can achieve high accuracy and boost straight-through processing (STP) rates—freeing human experts to focus only on the most complex cases. The result is faster, smarter claims handling with less manual work. Trusted by companies like Aon, Canada Life, and Aviva, Appian has also been named a Leader in Everest Group's AI-enabled Claims Management Systems for Property & Casualty (P&C) Insurance – Products PEAK Matrix® Assessment 2025. The assessment considered several factors, including each provider's vision and strategy, technology capabilities, deployment flexibility, customer engagement models, support services, and overall value delivered. Appian's recognition as a Leader highlights its strength in embedding AI directly into processes. This approach enables insurers to easily access powerful AI capabilities exactly when and where they're needed—with just a few clicks. "Appian's Connected Claims solution, built on its low-code platform, combines AI-driven document processing, seamless third-party integrations, and configurable accelerators to deliver rapid time-to-value for P&C insurers," said Aurindum Mukherjee, Practice Director at Everest Group. "Strong integration support across payment, risk, and fraud systems, coupled with proven success driving accelerated business value for insurers and high client satisfaction for implementation and support, underpins Appian's position as a Leader in Everest Group's AI-enabled Claims Management Systems PEAK Matrix® Assessment 2025." "We are launching Appian Connected Claims 2.0 to meet the urgent need for speed and early value realisation as the insurance industry tackles complexity, " said Jake Sloan, Global Vice President of Insurance, Appian. "Our solution drives digital-first claims innovation, aligning with core admin cloud modernisation for early value realisation. It's configurable, rapidly deployable, and leverages the latest powerful AI in Process to accelerate cycles, combat fraud, and personalise customer experiences. Connected Claims 2.0 empowers insurers to transform operations, balancing efficiency and accuracy with superior customer satisfaction, truly leading the evolution of claims management." Connected Claims 2.0 supports insurance companies, from claims adjusters, fraud detection teams, customer service representatives, regulatory compliance teams, to IT and operations teams. About Appian Appian is The Process Company. We deliver a software platform that helps organisations run better processes that reduce costs, improve customer experiences, and gain a strategic edge. Committed to client success, we serve many of the world's largest companies across various industries. For more information, visit [Nasdaq: APPN] Follow Appian: LinkedIn, X (Twitter) DisclaimerLicensed extracts taken from Everest Group's PEAK Matrix® Reports, may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group's PEAK Matrix® reports do not necessarily provide the full context of our research and analysis. All research and analysis conducted by Everest Group's analysts and included in Everest Group's PEAK Matrix® reports is independent and no organization has paid a fee to be featured or to influence their ranking. To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix® Reports. About Everest GroupEverest Group is a leading global research firm helping business leaders make confident Group's PEAK Matrix® assessments provide the analysis and insights enterprises need to make critical selection decisions about global services providers, locations, and products and solutions within various market segments. Likewise, providers of these services, products, and solutions, look to the PEAK Matrix® to gauge and calibrate their offerings against others in the industry or market. Find further details and in-depth content at View original content: SOURCE Appian Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
